Advertisement

Drug Safety

, Volume 31, Issue 9, pp 743–752 | Cite as

RevAssist®

A Comprehensive Risk Minimization Programme for Preventing Fetal Exposure to Lenalidomide
  • Carmen P. Castaneda
  • Jerome B. Zeldis
  • John Freeman
  • Curtis Quigley
  • Nancy A. Brandenburg
  • Robert Bwire
Practical Drug Safety

Abstract

Lenalidomide (Revlimid®) is an immunomodulatory drug and an analogue of thalidomide, a known teratogen. To prevent fetal exposure, in the US lenalidomide is available only under a special restricted distribution programme called RevAssist®. Under this risk minimization programme, only prescribers and contract pharmacies registered with the programme are able to prescribe and dispense the product. Patients must be advised of, agree to and comply with the requirements of the RevAssist® programme in order to receive lenalidomide through a registered prescriber. A total of 15 584 patients were registered in the RevAssist® programme during the first year lenalidomide was on the market. There were four reports of false-positive β-human chorionic gonadotrophin measurements in patients aged 43–57 years. Mandatory patient and prescriber surveys have shown discrepant responses that were resolved by risk management intervention specialists 99% of the time. The voluntary patient surveys have shown understanding of the risks of lenalidomide use and of behaviours necessary to minimize risks in >95% of females of childbearing potential and adult males. To date, there have been no reports of pregnancy in female patients or female partners of male patients. The pharmacy audit findings showed compliance with Rev Assist® was high. Although RevAssist® is labour-intensive, time-consuming and costly, it continues to be effective in preventing fetal exposure to lenalidomide.

Keywords

Thalidomide Lenalidomide Birth Control Method Fetal Exposure Voluntary Survey 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank Maria Luisa Salomon and her Risk Management Intervention Specialist Group for providing all the pertinent reports for this manuscript and Helen Cammisa-Parks for providing editorial support. The authors are all employees of Celgene Corporation and have stock ownership with the company. Jerome Zeldis is Chief Medical Officer at Celgene and receives remuneration for expert testimony and pending and received patents. No funding was provided for the preparation of this review.

References

  1. 1.
    Revlimid [package insert]. Summit (NJ): Celgene Corporation, 2007Google Scholar
  2. 2.
    Christian MS, Laskin OL, Sharper V, et al. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res (Part B) 2007; 80: 188–207CrossRefGoogle Scholar
  3. 3.
    FDA. Food and Drug Administration guidance for industry: premarketing risk assessment [online]. Available from URL: http://www.fda.gov/cder/guidance/6357fnl.htm [Accessed 2007 Jul 5]
  4. 4.
    FDA. Food and Drug Administration guidance for industry: development and use of risk minimization action plans [online]. Available from URL: http://www.fda.gov/cder/guidance/6358fnl.htm [Accessed 2007 Jul 5]
  5. 5.
    FDA. Food and Drug Administration guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment [online]. Available from URL: http://www.fda.gov/cder/guidance/6359OCC.pdf [Accessed 2007 Jul 5]
  6. 6.
    Uhl K, Trontell A, Kennedy D. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools. Pharmacoepidemiol Drug Saf 2007; 16: 337–48PubMedCrossRefGoogle Scholar
  7. 7.
    Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21(2): 319–30PubMedCrossRefGoogle Scholar
  8. 8.
    Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006; 29(4): 321–9PubMedCrossRefGoogle Scholar
  9. 9.
    Segal EA, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European Bosentan Surveillance Programmes. Drug Saf 2005; 28(11): 971–80PubMedCrossRefGoogle Scholar
  10. 10.
    Honein M, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens? The iPLEDGE test case. Drug Saf 2007; 30(1): 5–15PubMedCrossRefGoogle Scholar
  11. 11.
    Stenman UH, Alfthan H, Ranta T, et al. Serum levels of human chorionic gonadotrophin in nonpregnant women and men are modulated by gonadotrophin-releasing hormone and sex steroids. J Clin Endocrinol Metab 1987; 64: 730–6PubMedCrossRefGoogle Scholar
  12. 12.
    Snyder J, Haymond S, Parvin C, et al. Diagnostic considerations in the measurement of human chorionic gonadotrophin in aging women. Clin Chem 2005; 51: 1830–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Carmen P. Castaneda
    • 1
  • Jerome B. Zeldis
    • 2
  • John Freeman
    • 1
  • Curtis Quigley
    • 3
  • Nancy A. Brandenburg
    • 1
  • Robert Bwire
    • 1
  1. 1.Global Drug SafetyCelgene CorporationSummitUSA
  2. 2.Medical Affairs AdministrationCelgene CorporationSummitUSA
  3. 3.Sales Operations and Healthcare ManagementCelgene CorporationSummitUSA

Personalised recommendations